{"id":389762,"date":"2022-11-11T00:00:00","date_gmt":"2022-11-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2022-biopharma-renal-cell-carcinoma-disease-landscape-forecast-g7-2022\/"},"modified":"2026-04-26T11:18:07","modified_gmt":"2026-04-26T11:18:07","slug":"dlsfon0009-2022-biopharma-renal-cell-carcinoma-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2022-biopharma-renal-cell-carcinoma-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Renal Cell Carcinoma | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>The renal cell carcinoma\u00a0market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb \/ Ono Pharmaceutical) and Keytruda (Merck &#038; Co.) plus Inlyta (Pfizer), are revolutionizing the treatment of advanced disease. The approval and uptake of Opdivo plus Cabometyx (Exelixis \/ Ipsen) and Keytruda plus Lenvima \/ Kisplyx (Eisai) will also drive fierce competition in this setting. Treatment choices for early-stage disease are also increasing with Keytruda\u2019s label expansion as an adjuvant therapy. Moreover, the FDA\u2019s approval of Welireg (Merck &#038; Co.) will reshape the treatment of VHL-associated tumors. The anticipated entry of other agents such as savolitinib\u00a0(AstraZeneca) will further diversify treatment options during the forecast period and create a highly competitive and dynamic market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the size of the early-stage and advanced \/ metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?<\/li>\n<li>What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, Welireg, Lenvima \/ Kisplyx, and Keytruda for renal cell carcinoma?<\/li>\n<li>Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?<\/li>\n<li>What are the drivers and constraints in renal cell carcinoma, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389762","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-cell-carcinoma","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389762\/revisions"}],"predecessor-version":[{"id":576192,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389762\/revisions\/576192"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}